Indeed Snapshot

Track Supernus Pharmaceuticals reviews on Indeed to uncover insights on employee sentiment
Ticker Symbol Entity Name As Of Date Profile Url Name Website Industry Description Revenue Headquarters location CEO Rating: CEO (%) Rating: CEO Responses Count Rating: Overall Happiness: Compensation score Happiness: Support score Happiness: Purpose score Happiness: Flexibility score Happiness: Energy score Happiness: Work Happiness score Happiness: Trust score Happiness: Learning score Happiness: Belonging score Happiness: Inclusion score Happiness: Overall score Happiness: Appreciation score Happiness: Achievement score Happiness: Responses Count Review Count Ratings Responses Count Rating: Culture & Values Rating: Compensation & Benefits Rating: Job Security & Advancement Rating: Senior Management Rating: Worklife Balance Interview: Duration Responses count Interview Duration Interview: Difficulty Responses count Interview Difficulty Interview: Experience Responses count Interview Experience Work Culture: Stressful (0) to Relaxed (1) Ratio Work Culture: Slow Paced (0) to Fast Paced (1) Ratio Work Culture: Competitive (0) to Collaborative (1) Ratio Date Added Date Updated Sector Industry
nasdaq:supn https://www.indeed.com/cmp/supernus-pharmaceuticals Sep 11th, 2021 12:00AM Open Supernus Pharmaceuticals Pharmaceutical Supernus Pharmaceuticals wouldn't mind being a drug-maker superhero of sorts to epileptics. As a specialty pharmaceutical company, Supernus develops treatments for epilepsy and other central nervous system disorders. Its lead candidate is a once-daily, extended-release oral epilepsy drug developed from topiramate, an existing immediate-release drug that is administered multiple times daily. Another candidate, Epliga, is a similar epilepsy treatment developed from another immediate-release drug, oxcarbazepine. Both candidates are in late-stage development; other pipeline products include treatments for attention deficit hyperactivity disorder (ADHD). Supernus launched its initial public offering in 2012. The company intends to use a portion of the proceeds raised in its IPO (up to $57 million) to fund continued development of its two epilepsy drug candidates, as well as its other earlier-stage ADHD candidates. In addition, the company will likely use a portion of the proceeds to market and commercialize its lead epilepsy candidate, for which it intends to soon seek regulatory approval. Because its lead candidate is in the late-stages of development, the company intends to invest heavily in establishing in-house sales and marketing operations; it also plans to seek licensing agreements with other pharmaceutical companies to commercialize the product outside of the US. Upon FDA approval, the company would market its drug directly to physicians and neurologists in the US. Supernus faces competition from other companies also developing once-daily, extended-release topiramate products (Upsher-Smith Laboratories has such a candidate in late-stage development). As such one of its key priorities includes gaining exclusive marketing rights in the US, a designation that would position it as top supplier of topiramate products. The company faces similar challenges with its oxcarbazepine-based Epliga candidate, which if commercialized could compete in international markets with a similar candidate being developing by Desitin Arzneimittel GmbH. Topiramate was originally developed and marketed by Johnson & Johnson under the Topamax brand name; similarly, Novartis developed and marketed oxcarbazepine under the Trileptal brand. Neither product is exclusively owned by its original developers and both are available in generic form. Supernus is leveraging its proprietary drug development technologies to transform topiramate and oxcarbazepine into novel extended-release, once daily drug treatments. Supernus also uses its drug development technologies to earn revenue, mainly by licensing its technologies and services to other pharmaceutical companies. It also brings in royalty payments associated with certain drug products developed using its technologies. However, like many drug development companies investing heavily in R&D and other expenses, Supernus has not been profitable since its inception. The company, which traces its roots back to the early 1990s, started out as a stand-alone company and later became a subsidiary of Shire plc. The company broke from Shire in 2005 and formed its current business. Prior to its IPO, Supernus was a private firm owned by institutional investors, including New Enterprise Associates, which held a 45% stake; and OrbiMed Private Investments and Abingworth Bioventures, which each held an 18% stake. Company founder and CEO Jack A. Khattar also held a 10% stake through ownership of restricted stock. RRv1_UNDER_1M 3.90 11.00 11.00 3.20 3.70 3.30 3.30 3.30 13.00 About a month 16.00 MEDIUM 16.00 AVERAGE Sep 11th, 2021 07:33AM Sep 11th, 2021 07:33AM Health Care Pharmaceuticals & Biotechnology
nasdaq:supn https://www.indeed.com/cmp/supernus-pharmaceuticals Sep 10th, 2021 12:00AM Open Supernus Pharmaceuticals Pharmaceutical Supernus Pharmaceuticals wouldn't mind being a drug-maker superhero of sorts to epileptics. As a specialty pharmaceutical company, Supernus develops treatments for epilepsy and other central nervous system disorders. Its lead candidate is a once-daily, extended-release oral epilepsy drug developed from topiramate, an existing immediate-release drug that is administered multiple times daily. Another candidate, Epliga, is a similar epilepsy treatment developed from another immediate-release drug, oxcarbazepine. Both candidates are in late-stage development; other pipeline products include treatments for attention deficit hyperactivity disorder (ADHD). Supernus launched its initial public offering in 2012. The company intends to use a portion of the proceeds raised in its IPO (up to $57 million) to fund continued development of its two epilepsy drug candidates, as well as its other earlier-stage ADHD candidates. In addition, the company will likely use a portion of the proceeds to market and commercialize its lead epilepsy candidate, for which it intends to soon seek regulatory approval. Because its lead candidate is in the late-stages of development, the company intends to invest heavily in establishing in-house sales and marketing operations; it also plans to seek licensing agreements with other pharmaceutical companies to commercialize the product outside of the US. Upon FDA approval, the company would market its drug directly to physicians and neurologists in the US. Supernus faces competition from other companies also developing once-daily, extended-release topiramate products (Upsher-Smith Laboratories has such a candidate in late-stage development). As such one of its key priorities includes gaining exclusive marketing rights in the US, a designation that would position it as top supplier of topiramate products. The company faces similar challenges with its oxcarbazepine-based Epliga candidate, which if commercialized could compete in international markets with a similar candidate being developing by Desitin Arzneimittel GmbH. Topiramate was originally developed and marketed by Johnson & Johnson under the Topamax brand name; similarly, Novartis developed and marketed oxcarbazepine under the Trileptal brand. Neither product is exclusively owned by its original developers and both are available in generic form. Supernus is leveraging its proprietary drug development technologies to transform topiramate and oxcarbazepine into novel extended-release, once daily drug treatments. Supernus also uses its drug development technologies to earn revenue, mainly by licensing its technologies and services to other pharmaceutical companies. It also brings in royalty payments associated with certain drug products developed using its technologies. However, like many drug development companies investing heavily in R&D and other expenses, Supernus has not been profitable since its inception. The company, which traces its roots back to the early 1990s, started out as a stand-alone company and later became a subsidiary of Shire plc. The company broke from Shire in 2005 and formed its current business. Prior to its IPO, Supernus was a private firm owned by institutional investors, including New Enterprise Associates, which held a 45% stake; and OrbiMed Private Investments and Abingworth Bioventures, which each held an 18% stake. Company founder and CEO Jack A. Khattar also held a 10% stake through ownership of restricted stock. RRv1_UNDER_1M 3.90 11.00 11.00 3.20 3.70 3.30 3.30 3.30 13.00 About a month 16.00 MEDIUM 16.00 AVERAGE Sep 10th, 2021 08:02AM Sep 10th, 2021 08:02AM Health Care Pharmaceuticals & Biotechnology
nasdaq:supn https://www.indeed.com/cmp/supernus-pharmaceuticals Sep 9th, 2021 12:00AM Open Supernus Pharmaceuticals Pharmaceutical Supernus Pharmaceuticals wouldn't mind being a drug-maker superhero of sorts to epileptics. As a specialty pharmaceutical company, Supernus develops treatments for epilepsy and other central nervous system disorders. Its lead candidate is a once-daily, extended-release oral epilepsy drug developed from topiramate, an existing immediate-release drug that is administered multiple times daily. Another candidate, Epliga, is a similar epilepsy treatment developed from another immediate-release drug, oxcarbazepine. Both candidates are in late-stage development; other pipeline products include treatments for attention deficit hyperactivity disorder (ADHD). Supernus launched its initial public offering in 2012. The company intends to use a portion of the proceeds raised in its IPO (up to $57 million) to fund continued development of its two epilepsy drug candidates, as well as its other earlier-stage ADHD candidates. In addition, the company will likely use a portion of the proceeds to market and commercialize its lead epilepsy candidate, for which it intends to soon seek regulatory approval. Because its lead candidate is in the late-stages of development, the company intends to invest heavily in establishing in-house sales and marketing operations; it also plans to seek licensing agreements with other pharmaceutical companies to commercialize the product outside of the US. Upon FDA approval, the company would market its drug directly to physicians and neurologists in the US. Supernus faces competition from other companies also developing once-daily, extended-release topiramate products (Upsher-Smith Laboratories has such a candidate in late-stage development). As such one of its key priorities includes gaining exclusive marketing rights in the US, a designation that would position it as top supplier of topiramate products. The company faces similar challenges with its oxcarbazepine-based Epliga candidate, which if commercialized could compete in international markets with a similar candidate being developing by Desitin Arzneimittel GmbH. Topiramate was originally developed and marketed by Johnson & Johnson under the Topamax brand name; similarly, Novartis developed and marketed oxcarbazepine under the Trileptal brand. Neither product is exclusively owned by its original developers and both are available in generic form. Supernus is leveraging its proprietary drug development technologies to transform topiramate and oxcarbazepine into novel extended-release, once daily drug treatments. Supernus also uses its drug development technologies to earn revenue, mainly by licensing its technologies and services to other pharmaceutical companies. It also brings in royalty payments associated with certain drug products developed using its technologies. However, like many drug development companies investing heavily in R&D and other expenses, Supernus has not been profitable since its inception. The company, which traces its roots back to the early 1990s, started out as a stand-alone company and later became a subsidiary of Shire plc. The company broke from Shire in 2005 and formed its current business. Prior to its IPO, Supernus was a private firm owned by institutional investors, including New Enterprise Associates, which held a 45% stake; and OrbiMed Private Investments and Abingworth Bioventures, which each held an 18% stake. Company founder and CEO Jack A. Khattar also held a 10% stake through ownership of restricted stock. RRv1_UNDER_1M 3.90 11.00 11.00 3.20 3.70 3.30 3.30 3.30 13.00 About a month 16.00 MEDIUM 16.00 AVERAGE Sep 9th, 2021 06:25AM Sep 9th, 2021 06:25AM Health Care Pharmaceuticals & Biotechnology
nasdaq:supn https://www.indeed.com/cmp/supernus-pharmaceuticals Sep 6th, 2021 12:00AM Open Supernus Pharmaceuticals Pharmaceutical Supernus Pharmaceuticals wouldn't mind being a drug-maker superhero of sorts to epileptics. As a specialty pharmaceutical company, Supernus develops treatments for epilepsy and other central nervous system disorders. Its lead candidate is a once-daily, extended-release oral epilepsy drug developed from topiramate, an existing immediate-release drug that is administered multiple times daily. Another candidate, Epliga, is a similar epilepsy treatment developed from another immediate-release drug, oxcarbazepine. Both candidates are in late-stage development; other pipeline products include treatments for attention deficit hyperactivity disorder (ADHD). Supernus launched its initial public offering in 2012. The company intends to use a portion of the proceeds raised in its IPO (up to $57 million) to fund continued development of its two epilepsy drug candidates, as well as its other earlier-stage ADHD candidates. In addition, the company will likely use a portion of the proceeds to market and commercialize its lead epilepsy candidate, for which it intends to soon seek regulatory approval. Because its lead candidate is in the late-stages of development, the company intends to invest heavily in establishing in-house sales and marketing operations; it also plans to seek licensing agreements with other pharmaceutical companies to commercialize the product outside of the US. Upon FDA approval, the company would market its drug directly to physicians and neurologists in the US. Supernus faces competition from other companies also developing once-daily, extended-release topiramate products (Upsher-Smith Laboratories has such a candidate in late-stage development). As such one of its key priorities includes gaining exclusive marketing rights in the US, a designation that would position it as top supplier of topiramate products. The company faces similar challenges with its oxcarbazepine-based Epliga candidate, which if commercialized could compete in international markets with a similar candidate being developing by Desitin Arzneimittel GmbH. Topiramate was originally developed and marketed by Johnson & Johnson under the Topamax brand name; similarly, Novartis developed and marketed oxcarbazepine under the Trileptal brand. Neither product is exclusively owned by its original developers and both are available in generic form. Supernus is leveraging its proprietary drug development technologies to transform topiramate and oxcarbazepine into novel extended-release, once daily drug treatments. Supernus also uses its drug development technologies to earn revenue, mainly by licensing its technologies and services to other pharmaceutical companies. It also brings in royalty payments associated with certain drug products developed using its technologies. However, like many drug development companies investing heavily in R&D and other expenses, Supernus has not been profitable since its inception. The company, which traces its roots back to the early 1990s, started out as a stand-alone company and later became a subsidiary of Shire plc. The company broke from Shire in 2005 and formed its current business. Prior to its IPO, Supernus was a private firm owned by institutional investors, including New Enterprise Associates, which held a 45% stake; and OrbiMed Private Investments and Abingworth Bioventures, which each held an 18% stake. Company founder and CEO Jack A. Khattar also held a 10% stake through ownership of restricted stock. RRv1_UNDER_1M 3.90 11.00 11.00 3.20 3.70 3.30 3.30 3.30 13.00 About a month 16.00 MEDIUM 16.00 AVERAGE Sep 6th, 2021 08:12AM Sep 6th, 2021 08:12AM Health Care Pharmaceuticals & Biotechnology
nasdaq:supn https://www.indeed.com/cmp/supernus-pharmaceuticals Sep 5th, 2021 12:00AM Open Supernus Pharmaceuticals Pharmaceutical Supernus Pharmaceuticals wouldn't mind being a drug-maker superhero of sorts to epileptics. As a specialty pharmaceutical company, Supernus develops treatments for epilepsy and other central nervous system disorders. Its lead candidate is a once-daily, extended-release oral epilepsy drug developed from topiramate, an existing immediate-release drug that is administered multiple times daily. Another candidate, Epliga, is a similar epilepsy treatment developed from another immediate-release drug, oxcarbazepine. Both candidates are in late-stage development; other pipeline products include treatments for attention deficit hyperactivity disorder (ADHD). Supernus launched its initial public offering in 2012. The company intends to use a portion of the proceeds raised in its IPO (up to $57 million) to fund continued development of its two epilepsy drug candidates, as well as its other earlier-stage ADHD candidates. In addition, the company will likely use a portion of the proceeds to market and commercialize its lead epilepsy candidate, for which it intends to soon seek regulatory approval. Because its lead candidate is in the late-stages of development, the company intends to invest heavily in establishing in-house sales and marketing operations; it also plans to seek licensing agreements with other pharmaceutical companies to commercialize the product outside of the US. Upon FDA approval, the company would market its drug directly to physicians and neurologists in the US. Supernus faces competition from other companies also developing once-daily, extended-release topiramate products (Upsher-Smith Laboratories has such a candidate in late-stage development). As such one of its key priorities includes gaining exclusive marketing rights in the US, a designation that would position it as top supplier of topiramate products. The company faces similar challenges with its oxcarbazepine-based Epliga candidate, which if commercialized could compete in international markets with a similar candidate being developing by Desitin Arzneimittel GmbH. Topiramate was originally developed and marketed by Johnson & Johnson under the Topamax brand name; similarly, Novartis developed and marketed oxcarbazepine under the Trileptal brand. Neither product is exclusively owned by its original developers and both are available in generic form. Supernus is leveraging its proprietary drug development technologies to transform topiramate and oxcarbazepine into novel extended-release, once daily drug treatments. Supernus also uses its drug development technologies to earn revenue, mainly by licensing its technologies and services to other pharmaceutical companies. It also brings in royalty payments associated with certain drug products developed using its technologies. However, like many drug development companies investing heavily in R&D and other expenses, Supernus has not been profitable since its inception. The company, which traces its roots back to the early 1990s, started out as a stand-alone company and later became a subsidiary of Shire plc. The company broke from Shire in 2005 and formed its current business. Prior to its IPO, Supernus was a private firm owned by institutional investors, including New Enterprise Associates, which held a 45% stake; and OrbiMed Private Investments and Abingworth Bioventures, which each held an 18% stake. Company founder and CEO Jack A. Khattar also held a 10% stake through ownership of restricted stock. RRv1_UNDER_1M 3.90 11.00 11.00 3.20 3.70 3.30 3.30 3.30 13.00 About a month 16.00 MEDIUM 16.00 AVERAGE Sep 5th, 2021 09:00AM Sep 5th, 2021 09:00AM Health Care Pharmaceuticals & Biotechnology
nasdaq:supn https://www.indeed.com/cmp/supernus-pharmaceuticals Sep 3rd, 2021 12:00AM Open Supernus Pharmaceuticals Pharmaceutical Supernus Pharmaceuticals wouldn't mind being a drug-maker superhero of sorts to epileptics. As a specialty pharmaceutical company, Supernus develops treatments for epilepsy and other central nervous system disorders. Its lead candidate is a once-daily, extended-release oral epilepsy drug developed from topiramate, an existing immediate-release drug that is administered multiple times daily. Another candidate, Epliga, is a similar epilepsy treatment developed from another immediate-release drug, oxcarbazepine. Both candidates are in late-stage development; other pipeline products include treatments for attention deficit hyperactivity disorder (ADHD). Supernus launched its initial public offering in 2012. The company intends to use a portion of the proceeds raised in its IPO (up to $57 million) to fund continued development of its two epilepsy drug candidates, as well as its other earlier-stage ADHD candidates. In addition, the company will likely use a portion of the proceeds to market and commercialize its lead epilepsy candidate, for which it intends to soon seek regulatory approval. Because its lead candidate is in the late-stages of development, the company intends to invest heavily in establishing in-house sales and marketing operations; it also plans to seek licensing agreements with other pharmaceutical companies to commercialize the product outside of the US. Upon FDA approval, the company would market its drug directly to physicians and neurologists in the US. Supernus faces competition from other companies also developing once-daily, extended-release topiramate products (Upsher-Smith Laboratories has such a candidate in late-stage development). As such one of its key priorities includes gaining exclusive marketing rights in the US, a designation that would position it as top supplier of topiramate products. The company faces similar challenges with its oxcarbazepine-based Epliga candidate, which if commercialized could compete in international markets with a similar candidate being developing by Desitin Arzneimittel GmbH. Topiramate was originally developed and marketed by Johnson & Johnson under the Topamax brand name; similarly, Novartis developed and marketed oxcarbazepine under the Trileptal brand. Neither product is exclusively owned by its original developers and both are available in generic form. Supernus is leveraging its proprietary drug development technologies to transform topiramate and oxcarbazepine into novel extended-release, once daily drug treatments. Supernus also uses its drug development technologies to earn revenue, mainly by licensing its technologies and services to other pharmaceutical companies. It also brings in royalty payments associated with certain drug products developed using its technologies. However, like many drug development companies investing heavily in R&D and other expenses, Supernus has not been profitable since its inception. The company, which traces its roots back to the early 1990s, started out as a stand-alone company and later became a subsidiary of Shire plc. The company broke from Shire in 2005 and formed its current business. Prior to its IPO, Supernus was a private firm owned by institutional investors, including New Enterprise Associates, which held a 45% stake; and OrbiMed Private Investments and Abingworth Bioventures, which each held an 18% stake. Company founder and CEO Jack A. Khattar also held a 10% stake through ownership of restricted stock. RRv1_UNDER_1M 3.90 11.00 11.00 3.20 3.70 3.30 3.30 3.30 13.00 About a month 16.00 MEDIUM 16.00 AVERAGE Sep 3rd, 2021 08:53AM Sep 3rd, 2021 08:53AM Health Care Pharmaceuticals & Biotechnology
nasdaq:supn https://www.indeed.com/cmp/supernus-pharmaceuticals Sep 2nd, 2021 12:00AM Open Supernus Pharmaceuticals Pharmaceutical Supernus Pharmaceuticals wouldn't mind being a drug-maker superhero of sorts to epileptics. As a specialty pharmaceutical company, Supernus develops treatments for epilepsy and other central nervous system disorders. Its lead candidate is a once-daily, extended-release oral epilepsy drug developed from topiramate, an existing immediate-release drug that is administered multiple times daily. Another candidate, Epliga, is a similar epilepsy treatment developed from another immediate-release drug, oxcarbazepine. Both candidates are in late-stage development; other pipeline products include treatments for attention deficit hyperactivity disorder (ADHD). Supernus launched its initial public offering in 2012. The company intends to use a portion of the proceeds raised in its IPO (up to $57 million) to fund continued development of its two epilepsy drug candidates, as well as its other earlier-stage ADHD candidates. In addition, the company will likely use a portion of the proceeds to market and commercialize its lead epilepsy candidate, for which it intends to soon seek regulatory approval. Because its lead candidate is in the late-stages of development, the company intends to invest heavily in establishing in-house sales and marketing operations; it also plans to seek licensing agreements with other pharmaceutical companies to commercialize the product outside of the US. Upon FDA approval, the company would market its drug directly to physicians and neurologists in the US. Supernus faces competition from other companies also developing once-daily, extended-release topiramate products (Upsher-Smith Laboratories has such a candidate in late-stage development). As such one of its key priorities includes gaining exclusive marketing rights in the US, a designation that would position it as top supplier of topiramate products. The company faces similar challenges with its oxcarbazepine-based Epliga candidate, which if commercialized could compete in international markets with a similar candidate being developing by Desitin Arzneimittel GmbH. Topiramate was originally developed and marketed by Johnson & Johnson under the Topamax brand name; similarly, Novartis developed and marketed oxcarbazepine under the Trileptal brand. Neither product is exclusively owned by its original developers and both are available in generic form. Supernus is leveraging its proprietary drug development technologies to transform topiramate and oxcarbazepine into novel extended-release, once daily drug treatments. Supernus also uses its drug development technologies to earn revenue, mainly by licensing its technologies and services to other pharmaceutical companies. It also brings in royalty payments associated with certain drug products developed using its technologies. However, like many drug development companies investing heavily in R&D and other expenses, Supernus has not been profitable since its inception. The company, which traces its roots back to the early 1990s, started out as a stand-alone company and later became a subsidiary of Shire plc. The company broke from Shire in 2005 and formed its current business. Prior to its IPO, Supernus was a private firm owned by institutional investors, including New Enterprise Associates, which held a 45% stake; and OrbiMed Private Investments and Abingworth Bioventures, which each held an 18% stake. Company founder and CEO Jack A. Khattar also held a 10% stake through ownership of restricted stock. RRv1_UNDER_1M 3.90 11.00 11.00 3.20 3.70 3.30 3.30 3.30 13.00 About a month 16.00 MEDIUM 16.00 AVERAGE Sep 2nd, 2021 06:12AM Sep 2nd, 2021 06:12AM Health Care Pharmaceuticals & Biotechnology
nasdaq:supn https://www.indeed.com/cmp/supernus-pharmaceuticals Sep 1st, 2021 12:00AM Open Supernus Pharmaceuticals Pharmaceutical Supernus Pharmaceuticals wouldn't mind being a drug-maker superhero of sorts to epileptics. As a specialty pharmaceutical company, Supernus develops treatments for epilepsy and other central nervous system disorders. Its lead candidate is a once-daily, extended-release oral epilepsy drug developed from topiramate, an existing immediate-release drug that is administered multiple times daily. Another candidate, Epliga, is a similar epilepsy treatment developed from another immediate-release drug, oxcarbazepine. Both candidates are in late-stage development; other pipeline products include treatments for attention deficit hyperactivity disorder (ADHD). Supernus launched its initial public offering in 2012. The company intends to use a portion of the proceeds raised in its IPO (up to $57 million) to fund continued development of its two epilepsy drug candidates, as well as its other earlier-stage ADHD candidates. In addition, the company will likely use a portion of the proceeds to market and commercialize its lead epilepsy candidate, for which it intends to soon seek regulatory approval. Because its lead candidate is in the late-stages of development, the company intends to invest heavily in establishing in-house sales and marketing operations; it also plans to seek licensing agreements with other pharmaceutical companies to commercialize the product outside of the US. Upon FDA approval, the company would market its drug directly to physicians and neurologists in the US. Supernus faces competition from other companies also developing once-daily, extended-release topiramate products (Upsher-Smith Laboratories has such a candidate in late-stage development). As such one of its key priorities includes gaining exclusive marketing rights in the US, a designation that would position it as top supplier of topiramate products. The company faces similar challenges with its oxcarbazepine-based Epliga candidate, which if commercialized could compete in international markets with a similar candidate being developing by Desitin Arzneimittel GmbH. Topiramate was originally developed and marketed by Johnson & Johnson under the Topamax brand name; similarly, Novartis developed and marketed oxcarbazepine under the Trileptal brand. Neither product is exclusively owned by its original developers and both are available in generic form. Supernus is leveraging its proprietary drug development technologies to transform topiramate and oxcarbazepine into novel extended-release, once daily drug treatments. Supernus also uses its drug development technologies to earn revenue, mainly by licensing its technologies and services to other pharmaceutical companies. It also brings in royalty payments associated with certain drug products developed using its technologies. However, like many drug development companies investing heavily in R&D and other expenses, Supernus has not been profitable since its inception. The company, which traces its roots back to the early 1990s, started out as a stand-alone company and later became a subsidiary of Shire plc. The company broke from Shire in 2005 and formed its current business. Prior to its IPO, Supernus was a private firm owned by institutional investors, including New Enterprise Associates, which held a 45% stake; and OrbiMed Private Investments and Abingworth Bioventures, which each held an 18% stake. Company founder and CEO Jack A. Khattar also held a 10% stake through ownership of restricted stock. RRv1_UNDER_1M 3.90 11.00 11.00 3.20 3.70 3.30 3.30 3.30 13.00 About a month 16.00 MEDIUM 16.00 AVERAGE Sep 1st, 2021 07:50AM Sep 1st, 2021 07:50AM Health Care Pharmaceuticals & Biotechnology
nasdaq:supn https://www.indeed.com/cmp/supernus-pharmaceuticals Aug 30th, 2021 12:00AM Open Supernus Pharmaceuticals Pharmaceutical Supernus Pharmaceuticals wouldn't mind being a drug-maker superhero of sorts to epileptics. As a specialty pharmaceutical company, Supernus develops treatments for epilepsy and other central nervous system disorders. Its lead candidate is a once-daily, extended-release oral epilepsy drug developed from topiramate, an existing immediate-release drug that is administered multiple times daily. Another candidate, Epliga, is a similar epilepsy treatment developed from another immediate-release drug, oxcarbazepine. Both candidates are in late-stage development; other pipeline products include treatments for attention deficit hyperactivity disorder (ADHD). Supernus launched its initial public offering in 2012. The company intends to use a portion of the proceeds raised in its IPO (up to $57 million) to fund continued development of its two epilepsy drug candidates, as well as its other earlier-stage ADHD candidates. In addition, the company will likely use a portion of the proceeds to market and commercialize its lead epilepsy candidate, for which it intends to soon seek regulatory approval. Because its lead candidate is in the late-stages of development, the company intends to invest heavily in establishing in-house sales and marketing operations; it also plans to seek licensing agreements with other pharmaceutical companies to commercialize the product outside of the US. Upon FDA approval, the company would market its drug directly to physicians and neurologists in the US. Supernus faces competition from other companies also developing once-daily, extended-release topiramate products (Upsher-Smith Laboratories has such a candidate in late-stage development). As such one of its key priorities includes gaining exclusive marketing rights in the US, a designation that would position it as top supplier of topiramate products. The company faces similar challenges with its oxcarbazepine-based Epliga candidate, which if commercialized could compete in international markets with a similar candidate being developing by Desitin Arzneimittel GmbH. Topiramate was originally developed and marketed by Johnson & Johnson under the Topamax brand name; similarly, Novartis developed and marketed oxcarbazepine under the Trileptal brand. Neither product is exclusively owned by its original developers and both are available in generic form. Supernus is leveraging its proprietary drug development technologies to transform topiramate and oxcarbazepine into novel extended-release, once daily drug treatments. Supernus also uses its drug development technologies to earn revenue, mainly by licensing its technologies and services to other pharmaceutical companies. It also brings in royalty payments associated with certain drug products developed using its technologies. However, like many drug development companies investing heavily in R&D and other expenses, Supernus has not been profitable since its inception. The company, which traces its roots back to the early 1990s, started out as a stand-alone company and later became a subsidiary of Shire plc. The company broke from Shire in 2005 and formed its current business. Prior to its IPO, Supernus was a private firm owned by institutional investors, including New Enterprise Associates, which held a 45% stake; and OrbiMed Private Investments and Abingworth Bioventures, which each held an 18% stake. Company founder and CEO Jack A. Khattar also held a 10% stake through ownership of restricted stock. RRv1_UNDER_1M 3.90 11.00 11.00 3.20 3.70 3.30 3.30 3.30 13.00 About a month 16.00 MEDIUM 16.00 AVERAGE Aug 30th, 2021 07:28AM Aug 30th, 2021 07:28AM Health Care Pharmaceuticals & Biotechnology
nasdaq:supn https://www.indeed.com/cmp/supernus-pharmaceuticals Aug 29th, 2021 12:00AM Open Supernus Pharmaceuticals Pharmaceutical Supernus Pharmaceuticals wouldn't mind being a drug-maker superhero of sorts to epileptics. As a specialty pharmaceutical company, Supernus develops treatments for epilepsy and other central nervous system disorders. Its lead candidate is a once-daily, extended-release oral epilepsy drug developed from topiramate, an existing immediate-release drug that is administered multiple times daily. Another candidate, Epliga, is a similar epilepsy treatment developed from another immediate-release drug, oxcarbazepine. Both candidates are in late-stage development; other pipeline products include treatments for attention deficit hyperactivity disorder (ADHD). Supernus launched its initial public offering in 2012. The company intends to use a portion of the proceeds raised in its IPO (up to $57 million) to fund continued development of its two epilepsy drug candidates, as well as its other earlier-stage ADHD candidates. In addition, the company will likely use a portion of the proceeds to market and commercialize its lead epilepsy candidate, for which it intends to soon seek regulatory approval. Because its lead candidate is in the late-stages of development, the company intends to invest heavily in establishing in-house sales and marketing operations; it also plans to seek licensing agreements with other pharmaceutical companies to commercialize the product outside of the US. Upon FDA approval, the company would market its drug directly to physicians and neurologists in the US. Supernus faces competition from other companies also developing once-daily, extended-release topiramate products (Upsher-Smith Laboratories has such a candidate in late-stage development). As such one of its key priorities includes gaining exclusive marketing rights in the US, a designation that would position it as top supplier of topiramate products. The company faces similar challenges with its oxcarbazepine-based Epliga candidate, which if commercialized could compete in international markets with a similar candidate being developing by Desitin Arzneimittel GmbH. Topiramate was originally developed and marketed by Johnson & Johnson under the Topamax brand name; similarly, Novartis developed and marketed oxcarbazepine under the Trileptal brand. Neither product is exclusively owned by its original developers and both are available in generic form. Supernus is leveraging its proprietary drug development technologies to transform topiramate and oxcarbazepine into novel extended-release, once daily drug treatments. Supernus also uses its drug development technologies to earn revenue, mainly by licensing its technologies and services to other pharmaceutical companies. It also brings in royalty payments associated with certain drug products developed using its technologies. However, like many drug development companies investing heavily in R&D and other expenses, Supernus has not been profitable since its inception. The company, which traces its roots back to the early 1990s, started out as a stand-alone company and later became a subsidiary of Shire plc. The company broke from Shire in 2005 and formed its current business. Prior to its IPO, Supernus was a private firm owned by institutional investors, including New Enterprise Associates, which held a 45% stake; and OrbiMed Private Investments and Abingworth Bioventures, which each held an 18% stake. Company founder and CEO Jack A. Khattar also held a 10% stake through ownership of restricted stock. RRv1_UNDER_1M 3.90 11.00 11.00 3.20 3.70 3.30 3.30 3.30 13.00 About a month 16.00 MEDIUM 16.00 AVERAGE Aug 29th, 2021 07:38AM Aug 29th, 2021 07:38AM Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.